Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for ruxolitinib cream (Opzelura) for the treatment of atopic dermatitis (AD) in patients 12 years of age and older whose disease is not adequately controlled with conventional topical prescription therapies (topical calcineurin inhibitors, topical corticosteroids) or when those therapies are not advisable.